Literature DB >> 7695887

Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies.

L Nedergaard1, T Haerslev, G K Jacobsen.   

Abstract

Estrogen receptors (ER) status was investigated in 101 primary breast carcinomas and their axillary lymph node metastases to determine if the malignant cells retained or changed this phenotypic feature during the metastatic process. Immunohistochemistry with the ER-ICA kit (Abbott Laboratory) on formalin-fixed paraffin-embedded tissue was used (paraffin ER-ICA). The ER status in primary and secondary tumours was concordant in 80 patients (79%) and discordant in 21 (21%). Eighteen of these twenty-one patients had ER-positive primary tumours and ER-negative lymph node metastases. This discordance, which may be due to loss of ERs in the metastatic cells or tumour heterogeneity, could explain the well-known failure of endocrine treatment in some of the patients with ER-positive primary tumours. A new monoclonal antibody ID5 (DAKO) against ERs was applied on formalin-fixed paraffin-embedded tissue from 83 of these 101 primary carcinomas. These analyses and paraffin ER-ICA analyses were compared to prior analyses of the same 83 tumours using the ER-ICA kit on fresh frozen tissue ("gold standard", frozen ER-ICA). Kappa coefficient, sensitivity and specificity were 0.74, 0.96 and 0.75 for ID5 antibody, and 0.59, 0.72 and 0.96 for ER-ICA antibody on paraffin sections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695887     DOI: 10.1111/j.1699-0463.1995.tb01074.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  10 in total

1.  Retrieval of estradiol receptor in paraffin sections of resting porcine uteri by microwave treatment. Immunostaining patterns obtained with different primary antibodies.

Authors:  W D Sierralta; H H Thole
Journal:  Histochem Cell Biol       Date:  1996-05       Impact factor: 4.304

2.  Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.

Authors:  Fancai Zeng; Guoxiong Xu; Tiejun Zhou; Chengwan Yang; Xinyan Wang; Chun Peng; Hong Zhou
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

Review 3.  Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs.

Authors:  Z Fadoukhair; D Zardavas; M A Chad; T Goulioti; P Aftimos; M Piccart
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

Review 4.  The role of estrogen receptors in breast cancer metastasis.

Authors:  S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

5.  Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.

Authors:  Song Zhao; Lanwei Xu; Wenjun Liu; Cuixia Lv; Kai Zhang; Haidong Gao; Jianli Wang; Rong Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.

Authors:  Zi-Xiang Yao; Lin-Jie Lu; Rui-Jue Wang; Liang-Bin Jin; Sheng-Chun Liu; Hong-Yuan Li; Guo-Sheng Ren; Kai-Nan Wu; De-Lin Wang; Ling-Quan Kong
Journal:  Med Oncol       Date:  2013-12-05       Impact factor: 3.064

7.  High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers.

Authors:  Pablo Mandó; Manglio Rizzo; Constanza Perez de la Puente; Mercedes Maino; Carolina Ponce; Maria Teresa Pombo; Mora Amat; Maria Victoria Costanzo; Adrian Nervo; Jorge Nadal; Veronica Fabiano; Jose Loza; Carlos Martin Loza; Federico Colo; Chacon Reinaldo
Journal:  J Breast Cancer       Date:  2017-06-26       Impact factor: 3.588

8.  Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.

Authors:  Rares Georgescu; Monica Boros; Denisa Moncea; Orsolya Bauer; Marius-Florin Coros; Adela Oprea; Cosmin Moldovan; Cristian Podoleanu; Simona Stolnicu
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-09

9.  The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.

Authors:  Sasithorn Sujarittanakarn; Wanwisa Himakhun; Worawarn Worasawate; Wilairat Prasert
Journal:  Asian Pac J Cancer Prev       Date:  2020-06-01

10.  A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.

Authors:  Xi Jin; Yi-Zhou Jiang; Sheng Chen; Zhi-Ming Shao; Gen-Hong Di
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.